Menu

All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

SHOW SEARCH

Show Me the Money! Antimicrobials vs. Rapid Diagnostic Pipelines

Activity Downloads

To Participate

To participate in this continuing education activity:

  1. Review the activity description and objectives.
  2. View the activity.
  3. Complete the online post-test and activity evaluation.
A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) 

 
 View more SIDPEC Activities
 

NOTE: If you attended the live CE activity titled "Show Me the Money! Antimicrobials vs. Rapid Diagnostic Pipelines" that was held on October 3, 2017 at the SIDP Annual Meeting in San Diego, California, AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-17-419-L01-P), you are NOT eligible to also receive CE credit for this home-study activity.

Description

New antimicrobials are difficult to develop and costly to bring to market. The rapid identification of infectious micro-organisms can improve the selection and use of antimicrobials. This program will explore the pipelines in late stage development for new antibiotics and anti-fungal as well as rapid diagnostic platforms. How these issues work in to an effective antimicrobial stewardship program will also be discussed.

This is a featured CE activity on the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) website. SIDPEC is the educational hub of the Society of Infectious Diseases Pharmacists (SIDP). The SIDPEC portal provides educational activities on infectious disease pharmacotherapy for clinical pharmacists, health‐systems pharmacists, community pharmacists, and other allied‐health disciplines.

Learning Objectives

The target audience for this activity is pharmacists. At the completion of this activity, the participant will be able to:

  • Compare the pipelines for antibiotics and rapid diagnostic platforms, with a focus on late stage development
  • Discuss the advantages of funding development of antibiotics versus products for rapid diagnosis of microorganisms
  • Review how rapid diagnostics and new antibiotics complement each other as part of an effective antimicrobial stewardship program

Faculty

Romney M. Humphries, PhD D(ABMM)
Chief Science Officer
Accelerate Diagnostics
Tucson, Arizona

Melissa D. Johnson, PharmD, MHS, AAHIVP
Associate Professor of Medicine
Clinical Liaison Pharmacist
Duke Antimicrobial Outreach Network
Duke University Medical Center
Durham, North Carolina

Accreditation

Release Date: 10-3-2017
Expiration Date: 10-3-2019

Pharmacists

ACPE LogoThis activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-17-419-H01-P has been assigned to this home-study knowledge-based activity (initial release date 10-3-2017). This activity is approved for 0.75 contact hours (0.075 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. Dr. Humphries is a Consultant for Allergan, bioMerieux, DNAe, Shionogi, Luminex, and MicrobeDx, and a Speaker for Achaogen, Merck & Co., Inc., and Roche. Dr. Johnson is a Principal Investigator for Charles River Laboratories and Merck & Co., Inc., and an Author for UpToDate, Inc.

Please note: The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.

Funding

This activity is partially supported by educational grants from Accelerate Diagnostics, Inc., CutisPharma, Inc., and Merck & Co., Inc.

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Download Handout

Handout